Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 2, 2001, Pages 111-119

  Reiffel, James A ^a   Appel, Gerald ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Antiarrhythmic drugs; Creatinine clearance; QT interval; Torsade de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; BETAPACE AF; DISOPYRAMIDE; DOFETILIDE; IBUTILIDE; PROCAINAMIDE; QUINIDINE; SOTALOL;

AGE; AREA UNDER THE CURVE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG INFORMATION; DRUG PACKAGING; DRUG USE; FOOD AND DRUG ADMINISTRATION; GENDER; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; PRIORITY JOURNAL; QT INTERVAL; REVIEW; TORSADE DES POINTES;

EID: 0034761504     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600202     Document Type: Review

References (34)

1. Proarrhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications
2. Mechanisms and management of proarrhythmia
3. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia
4. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
5. Risks of initiating therapy with sotalol for treatment of atrial fibrillation
6. JTc prolongation with d,1-sotalol in women versus men
7. Sotalol proarrhythmia: A report of five cases and an audit of the use of sotalol in a teaching hospital
8. Management of patients with atrial fibrillation. A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association
9. Syncopal episodes associated with cisapride and concurrent drugs
10. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction
11. Clinical pharmacokinetics of sotalol
12. Sotalol-induced torsades de pointes in patients with renal failure
13. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals
14. Prescribing information: Betapace (sotalol HCl)
15. Bedside monitoring of the QT interval
16. Effects of aging and gender on QT dispersion in an overtly healthy population
17. Effects of the ventricular activation sequence on the JT interval
18. Optimum formulae for heart rate correction of the QT interval
19. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)
20. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values
21. Time for yet another QT correction algorithm? Bazett and beyond
22. Management of atrial fibrillation in setting of heart failure
23. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
24. The kidney in heart failure
25. The pharmacokinetics (PK) and pharmacodynamics (PD) of D-sotalol (DS) in subjects with renal failure (RF)
26. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
27. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol
28. Pharmacokinetics of newer drugs in patients with renal impairment (part II)
29. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
30. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials
31. Prediction of creatinine clearance from serum creatinine
32. A more accurate method of estimate glomerular filtration rate from serum creatinine: A new prediction equation